![]() |
Name |
Penazaphilone G
|
Molecular Formula | C46H54Cl2N2O8 | |
IUPAC Name* |
[(7S)-2-[4-[(7S)-7-acetyloxy-5-chloro-3-[(5S)-3,5-dimethylhepta-1,3-dienyl]-7-methyl-6,8-dioxoisoquinolin-2-yl]butyl]-5-chloro-3-[(5S)-3,5-dimethylhepta-1,3-dienyl]-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate
|
|
SMILES |
CC[C@H](C)C=C(C)C=CC1=CC2=C(C(=O)[C@@](C(=O)C2=CN1CCCCN3C=C4C(=C(C(=O)[C@@](C4=O)(C)OC(=O)C)Cl)C=C3C=CC(=C[C@@H](C)CC)C)(C)OC(=O)C)Cl
|
|
InChI |
InChI=1S/C46H54Cl2N2O8/c1-11-27(3)21-29(5)15-17-33-23-35-37(41(53)45(9,57-31(7)51)43(55)39(35)47)25-49(33)19-13-14-20-50-26-38-36(24-34(50)18-16-30(6)22-28(4)12-2)40(48)44(56)46(10,42(38)54)58-32(8)52/h15-18,21-28H,11-14,19-20H2,1-10H3/t27-,28-,45-,46-/m0/s1
|
|
InChIKey |
GXUYGLKNAQMTRM-KNWFILBFSA-N
|
|
Synonyms |
Penazaphilone G
|
|
CAS | NA | |
PubChem CID | 146682803 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 833.8 | ALogp: | 10.3 |
HBD: | 0 | HBA: | 10 |
Rotatable Bonds: | 17 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 127.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 58 | QED Weighted: | 0.061 |
Caco-2 Permeability: | -5.367 | MDCK Permeability: | 0.00002910 |
Pgp-inhibitor: | 1 | Pgp-substrate: | 0.01 |
Human Intestinal Absorption (HIA): | 0.06 | 20% Bioavailability (F20%): | 0.978 |
30% Bioavailability (F30%): | 0.949 |
Blood-Brain-Barrier Penetration (BBB): | 0.041 | Plasma Protein Binding (PPB): | 82.33% |
Volume Distribution (VD): | 3.714 | Fu: | 4.55% |
CYP1A2-inhibitor: | 0.228 | CYP1A2-substrate: | 0.182 |
CYP2C19-inhibitor: | 0.895 | CYP2C19-substrate: | 0.876 |
CYP2C9-inhibitor: | 0.971 | CYP2C9-substrate: | 0.019 |
CYP2D6-inhibitor: | 0.912 | CYP2D6-substrate: | 0.01 |
CYP3A4-inhibitor: | 0.992 | CYP3A4-substrate: | 0.879 |
Clearance (CL): | 3.27 | Half-life (T1/2): | 0.119 |
hERG Blockers: | 0.789 | Human Hepatotoxicity (H-HT): | 0.987 |
Drug-inuced Liver Injury (DILI): | 0.959 | AMES Toxicity: | 0.908 |
Rat Oral Acute Toxicity: | 0.184 | Maximum Recommended Daily Dose: | 0.853 |
Skin Sensitization: | 0.975 | Carcinogencity: | 0.477 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.949 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002463 | ![]() |
0.497 | D0WY9N | ![]() |
0.190 | ||
ENC001870 | ![]() |
0.466 | D0B1IP | ![]() |
0.189 | ||
ENC006052 | ![]() |
0.460 | D09HNR | ![]() |
0.180 | ||
ENC003220 | ![]() |
0.451 | D0MY8N | ![]() |
0.177 | ||
ENC003605 | ![]() |
0.448 | D06LNW | ![]() |
0.176 | ||
ENC003676 | ![]() |
0.400 | D0K3WO | ![]() |
0.174 | ||
ENC005593 | ![]() |
0.397 | D05QDC | ![]() |
0.170 | ||
ENC006053 | ![]() |
0.396 | D06BLQ | ![]() |
0.170 | ||
ENC001841 | ![]() |
0.373 | D0N1FS | ![]() |
0.168 | ||
ENC006054 | ![]() |
0.365 | D00KRT | ![]() |
0.168 |